Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07466550
PHASE1
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
Official title: A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Risankizumab
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-03-08
Completion Date
2027-01
Last Updated
2026-03-12
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Risankizumab
Intravenous (IV)
DRUG
Risankizumab
Subcutaneous (SC) Injections